Drug Type Small molecule drug |
Synonyms NRC 2694-A, NRC 2694A, NRC-2694-A + [2] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H26N4O3 |
InChIKeyWBKHQQZRHCECKK-UHFFFAOYSA-N |
CAS Registry936446-61-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous cell carcinoma of head and neck metastatic | Phase 2 | US | 30 Sep 2022 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | IN | 30 Sep 2022 | |
Squamous Cell Carcinoma | Phase 2 | - | - | |
Breast Cancer | Phase 1 | IN | - |